116 results
6-K
EX-99
BLRX
Bioline Rx Ltd
6 Aug 19
BioLineRx Reports Second Quarter 2019 Financial Results
7:11am
June 30, 2018. The small increase resulted primarily from higher expenses associated with the BL-8040 GENESIS and COMBAT clinical trials, offset … and six months ended June 30, 2019 primarily relates to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant
6-K
EX-99
BLRX
Bioline Rx Ltd
18 Aug 21
BioLineRx Reports Second Quarter 2021 Financial Results
7:01am
-134 study; offset by a decrease in expenses related to the GENESIS and COMBAT clinical trials for Motixafortide, and a timing difference related … with the Motixafortide GENESIS and COMBAT clinical trials and a timing difference related to a tax credit received in respect of AGI-134; offset
6-K
EX-99
BLRX
Bioline Rx Ltd
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am
in the comparable 2020 period, offset by lower expenses associated with the completed Motixafortide GENESIS and COMBAT clinical trials.
Sales … September 30, 2020 primarily relate to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering
6-K
EX-99
BLRX
Bioline Rx Ltd
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
period in 2019. The increase resulted primarily from consultancy services and market research for motixafortide offset by a decrease in payroll … and 2019 primarily relate to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering expenses and issuance
6-K
EX-99
BLRX
Bioline Rx Ltd
6 Aug 20
BioLineRx Reports Second Quarter 2020 Financial Results
7:47am
higher expenses associated with the motixafortide COMBAT and GENESIS clinical trials, offset by a decrease in expenses associated with the AGI-134 study … 30, 2019 primarily relate to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering expenses.
Net
6-K
EX-99
p8t6q
16 Mar 22
BioLineRx Reports Fourth Quarter 2021 Financial Results
7:11am
6-K
EX-1
e0zm3ixt
12 Nov 19
Current report (foreign)
6:21am
6-K
EX-99
mdmxef80y iu22dk
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
fdexehcm1 yllou4
12 Mar 20
BioLineRx Reports Year-End 2019 Financial Results
7:00am
6-K
EX-99
6b3xltehyui bdf45l
23 Feb 21
BioLineRx Reports Year-End 2020 Financial Results
7:02am
6-K
EX-99
v18b4je
6 Aug 19
BioLineRx Reports Second Quarter 2019 Financial Results
7:11am
6-K
EX-99
mi2bk31
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
1io3c y0btppg4hhn4sf
18 Aug 21
BioLineRx Reports Second Quarter 2021 Financial Results
7:01am
6-K
EX-99
doh98
14 May 19
BioLineRx Reports First Quarter 2019 Financial Results
7:00am
6-K
EX-99
wibjfq91lkm 4s
26 May 21
BioLineRx Reports First Quarter 2021 Financial Results
7:54am
6-K
EX-99
fataw 6nbkd6k5pcx
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
8pw24rx
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
6-K
EX-99
dg8yxmgbq5xzrtj3
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am
6-K
EX-3
cgc0xyp58m
12 Nov 19
Current report (foreign)
6:21am
6-K
EX-99
z0harpgldcyccbe0dle
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am